APIAHF developed an infographic around mental health & isolation. This infographic addresses ways to overcome feelings of emotional distress and anxiety, especially during an outbreak.
APIAHF has developed a brief factsheet for those wanting more information about the second COVID-19 booster shot. Translations will be coming soon.
APIAHF and our friends at Made to Save have come together to develop this comprehensive guide to help answer your most frequently asked questions regarding vaccinating your children and what Pfizer's emergency use authorization means for you and your loved ones. This resource is available in AA and NH/PI languages.
APIAHF and the COVID-19 Community Corps have created a factsheet with important information regarding COVID-19 booster shots, now that individuals 12 and older are eligible. Due to continuous updates on guidelines from the CDC, translations of the resource are currently being revised.
APIAHF created fact sheets on receiving the influenza (flu) vaccination during flu season in the United States. Translated into 33 different AA and NH/PI languages, this resource answers common questions and answers regarding flu to help you stay protected this year.
APIAHF and Vaccinate Your Family have created fact sheets on paying for vaccines and receiving the flu vaccination. Translated into 30 different AA and NHPI languages, this resource educates community members on paying for vaccines depending on insurance type and about the influenza vaccination.
APIAHF and the National Asian Pacific American Bar Association (NAPABA) have created fact cards for those who may be unsure of their rights to a COVID-19 vaccination. Translated into 26 different AA and NH/PI languages, this resource educates community members on the benefits of getting vaccinated and encourages them to receive their free COVID-19 vaccinations regardless of immigration status, health insurance coverage, and/or Social Security identification.
日本語 / Japanese
Native Hawaiian and Pacific Islander
Asian Language Cards
May 20, 2022
Media Statement: CDC Strengthens Recommendations and Expands Eligibility for COVID-19 Booster Shots — Following the May 19 meeting of the Advisory Committee on Immunization Practices’ (ACIP), CDC is expanding eligibility of COVID-19 vaccine booster doses to everyone 5 years of age and older. CDC now recommends that children ages 5 through 11 years should receive a booster shot 5 months after their initial Pfizer-BioNTech vaccination series. In addition, CDC is strengthening its recommendation that those 12 and older who are immunocompromised and those 50 and older should receive a second booster dose if it has been at least 4 months since their first. To learn more, please visit: CDC Strengthens Recommendations and Expands Eligibility for COVID-19 Booster Shots | CDC Online Newsroom | CDC
January 5, 2022
CDC is endorsing the Advisory Committee on Immunization Practices’ (ACIP) recommendation to expand eligibility of booster doses to those 12 to 15 years old. CDC now recommends that adolescents age 12 to 17 years old should receive a booster shot 5 months after their initial Pfizer-BioNTech vaccination series.
Data show that COVID-19 boosters help broaden and strengthen protection against Omicron and other SARS-CoV-2 variants. ACIP reviewed the available safety data following the administration of over 25 million vaccine doses in adolescents; COVID-19 vaccines are safe and effective.
At this time, only the Pfizer-BioNTech COVID-19 vaccine is authorized and recommended for adolescents aged 12-17.
January 4, 2022
CDC is updating our recommendation for when many people can receive a booster shot, shortening the interval from 6 months to 5 months for people who received the Pfizer-BioNTech COVID-19 Vaccine. This means that people can now receive an mRNA booster shot 5 months after completing their Pfizer-BioNTech primary series. The booster interval recommendation for people who received the J&J vaccine (2 months) or the Moderna vaccine (6 months), has not changed.
Additionally, consistent with our prior recommendation for adults, CDC is recommending that moderately or severely immunocompromised 5–11-year-olds receive an additional primary dose of vaccine 28 days after their second shot. At this time, only the Pfizer-BioNTech COVID-19 vaccine is authorized and recommended for children aged 5-11.
December 20, 2021
CDC Endorses ACIP’s Updated COVID-19 Vaccine Recommendations — CDC is endorsing updated recommendations made by the Advisory Committee on Immunization Practices (ACIP) for the prevention of COVID-19, expressing a clinical preference for individuals to receive an mRNA COVID-19 vaccine over Johnson & Johnson’s COVID-19 vaccine. ACIP’s unanimous recommendation followed a robust discussion of the latest evidence on vaccine effectiveness, vaccine safety and rare adverse events, and consideration of the U.S. vaccine supply. The U.S. supply of mRNA vaccines is abundant – with nearly 100 million doses in the field for immediate use. To learn more, please visit: CDC Endorses ACIP’s Updated COVID-19 Vaccine Recommendations | CDC Online Newsroom | CDC
September 24, 2021
This updated interim guidance from CDC allows for millions of Americans who are at highest risk for COVID-19 to receive a Pfizer-BioNTech COVID-19 booster shot to help increase their protection.
people 65 years and older and residents in long-term care settings should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
people aged 50–64 years with underlying medical conditions should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
people aged 18–49 years with underlying medical conditions may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks, and
people aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks.
December 10, 2021
CDC Expands COVID-19 Booster Recommendations to 16-and-17-year-olds - CDC is strengthening its booster recommendations and encouraging everyone 16 and older to receive a booster shot. Although we don’t have all the answers on the Omicron variant, initial data suggests that COVID-19 boosters help broaden and strengthen the protection against Omicron and other variants. We know that COVID-19 vaccines are safe and effective, and I strongly encourage adolescents ages 16 and 17 to get their booster if they are at least 6 months post their initial Pfizer vaccination series.”
At this time, only the Pfizer-BioNTech COVID-19 vaccine is authorized and recommended for adolescents aged 16 and 17. More information will be available on CDC’s website soon.
September 9, 2021
The Centers for Medicare & Medicaid Services (CMS), in collaboration with the Centers for Disease Control and Prevention (CDC), announced today that emergency regulations requiring vaccinations for nursing home workers will be expanded to include hospitals, dialysis facilities, ambulatory surgical settings, and home health agencies, among others, as a condition for participating in the Medicare and Medicaid programs. The decision was based on the continued and growing spread of the virus in health care settings, especially in parts of the U.S. with higher incidence of COVID-19.
August 12, 2021
Today, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow the use of an additional dose in certain immunocompromised individuals, specifically, solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
For a full summary of the FDA announcement, please visit: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised
July 27, 2021
Today, the Centers for Disease Control and Prevention (CDC) updated information for fully vaccinated people given new evidence on the B.1.617.2 (Delta) variant currently circulating in the United States. The new guidance recommends:
Fully vaccinated people to wear a mask in public indoor settings in areas of substantial or high transmission. To determine your county's level of transmission, please visit the CDC COVID Data Tracker here.
Universal indoor masking for all teachers, staff, students, and visitors to schools, regardless of vaccination status.
For a full summary of changes to the CDC Interim Public Health Recommendations for Fully Vaccinated People, please visit: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated-guidance.html.
July 13, 2021
FDA put out a statement on their website this afternoon. Here is what is known so far:
Based on an analysis of Vaccine Adverse Event Reporting (VAERS) data, there have been 100 preliminary reports of GBS following vaccination with the Johnson & Johnson (Janssen) COVID vaccine after approximately 12.5 million doses administered in the U.S.
Of these 100 reports of GBS, 95 of them were serious and required hospitalization. There was one reported death.
Although the available evidence suggests an association between the Johnson & Johnson vaccine and increased risk of GBS, it is insufficient to establish a causal relationship.
The FDA has evaluated the available data for the Johnson & Johnson COVID-19 Vaccine and continues to find the known and potential benefits clearly outweigh the known and potential risks.
No similar safety signal has been identified with the Moderna and Pfizer-BioNTech COVID-19 vaccines.
FDA continues to work with CDC to monitor reports of GBS following vaccination with the Johnson & Johnson COVID-19 Vaccine.
Each year in the United States, an estimated 3,000 to 6,000 people develop GBS. Most people fully recover from the disorder.
GBS has also been observed at an increased rate associated with certain vaccines, including certain seasonal influenza vaccines and the vaccine to prevent shingles (Zoster vaccine).
The updated versions of the J&J COVID-19 Vaccine Fact Sheets are available on the FDA website:
The Johnson & Johnson (Janssen) COVID-19 Vaccine EUA Fact Sheet for Vaccination Providers (fda.gov) has been revised to include a warning about GBS and notes that reports of adverse events suggest an increased risk of GBS.
The Johnson & Johnson (Janssen) COVID-19 Vaccine EUA Fact Sheet for Recipients and Caregivers 07122021 (fda.gov) has been revised to include information about GBS and notes that vaccine recipients should seek medical attention right away if they develop any of the following symptoms after receiving the Janssen COVID-19 Vaccine:
weakness or tingling sensations, especially in the legs or arms, that’s worsening and spreading to other parts of the body
difficulty walking; difficulty with facial movements, including speaking, chewing or swallowing
double vision or inability to move eyes
difficulty with bladder control or bowel function.
May 13, 2021
CDC updated the Interim Public Health Recommendations for Fully Vaccinated People to advise that fully vaccinated people no longer need to wear a mask or physically distance in any setting, except where required by federal, state, local, tribal, or territorial laws, rules, and regulations, including hospitals, nursing homes, schools, and any regulatory requirements of local business and workplace guidance. The Interim Public Health Recommendations for Fully Vaccinated People do not apply to healthcare settings. This means that staff, patients, residents and visitors should continue to wear masks as recommended in all healthcare facilities.
Healthcare facilities should continue to refer to the Updated Healthcare Infection Prevention and Control Recommendations in Response to COVID-19 Vaccination for recommendations regarding source control and physical distancing in healthcare settings. CDC is considering how or if the updates for the community should be applied in healthcare and will update the healthcare guidance accordingly. We will keep you informed if any changes are made to the guidance for healthcare settings.
May 12, 2021
The Advisory Committee of Immunization Practices (ACIP) affirmed the FDA’s authorization of Pfizer’s vaccine to children, ages 12-15. Its recommendation means that pediatricians and family physicians can begin administering the vaccine immediately.
To address questions about vaccines and misinformation, below are new informational tools, resources, and key points developed by CDC to support educational efforts.
New web page: COVID-19 Vaccines for Children and Teens provides information about the benefits of COVID-19 vaccines for adolescents aged 12 and older, how to find a vaccination provider for adolescents, and what to expect during and after vaccination.
New fact sheet: COVID-19 Vaccines for Preteens and Teens is a printable fact sheet for parents that explains the benefits of a COVID-19 vaccine for their children, safety information, and what to expect during and after vaccination.
New frequently asked questions: Two new FAQs address questions about the safety and benefits of COVID-19 vaccination for adolescents aged 12 and older.
Myth-buster about infertility: It is safe for people who would like to have a baby one day to get a COVID-19 vaccine. This question and answer explains why.
Key things to know: The web pages Key Things to Know about COVID-19 Vaccines and About COVID-19 Vaccines have been updated to include the recommendation that adolescents aged 12 and older get vaccinated.
Information for Healthcare and Vaccine Providers:
New pediatric toolkit: The Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit provides materials to help healthcare providers give parents clear and accurate information about COVID-19 vaccines. The toolkit includes answers to common questions, an explanation of how mRNA vaccines work, and printable materials to give to parents.
New FAQs about consent for minors: FAQs have been posted on the Pfizer-BioNTech product page for providers with information about consent, prescreening questions, and other issues related to the vaccination of minors.
Information for Community Groups:
Toolkit for community-based organizations: The Community-Based Organizations COVID-19 Vaccine Toolkit has been updated to include information and resources on COVID-19 vaccination for adolescents aged 12 and older.
April 23, 2021
From our partners at Morehouse School of Medicine National COVID-19 Resiliency Network
The U.S. Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) released a joint statement regarding their determination that the recommended pause regarding the use of the Janssen (Johnson & Johnson) COVID-19 vaccine should resume.
The statement follows the April 13, 2021 joint CDC and FDA that highlighted six cases of a rare and severe type of blood clot and low platelets, also known as thrombosis-thrombocytopenia syndrome (TTS) following administration of the Janssen COVID-19 Vaccine.
As of April 13, more than 6.8 million of the Janssen (Johnson & Johnson) COVID-19 Vaccine doses had been administered in the United States.
Today, the FDA and CDC confirmed that a total of 15 cases of TTS have been reported to the Vaccine Adverse Event Reporting System (VAERS).
These cases include the original six reported cases from April 13, 2021, joint CDC and FDA statement.
All of these cases occurred in women between the ages of 18 and 59, with a median age of 37 years, indicating symptom onset between 6 and 15 days after vaccination.
Community members should report adverse events following vaccination to the Vaccine Adverse Event Reporting System (VAERS).
Learn more: http://bit.ly/NCRNCOVIDNews